We are thrilled to announce that Smöltap has been selected as one of eight companies to receive strategic funding from the Rhode Island Life Science Hub (RILSH) as part of their latest $4.5 million investment round. This recognition marks a significant milestone for our team and validates our mission to transform infant and neonatal spinal tap procedures.
A Vote of Confidence in Our Vision
Being chosen by RILSH represents more than financial support—it’s a powerful endorsement of our commitment to improving care for our smallest and most vulnerable patients. As a Providence-based medical technology startup developing a Class I device specifically designed to aid in infant and neonatal spinal tap procedures, we’re proud to be part of Rhode Island’s burgeoning life sciences ecosystem.
“These investments underscore the momentum building across Rhode Island’s life sciences sector,” said Dr. Mark A. Turco, President and CEO of RILSH. This momentum is exactly what drew us to establish and grow Smoltap in the Ocean State, and we’re honored to contribute to Rhode Island’s emergence as a competitive destination for global biotech innovation.
What This Means for Smöltap
This RILSH funding will support critical early-stage milestones and accelerate our company development at a pivotal time. The nondilutive nature of this investment allows us to maintain our focus on what matters most: developing innovative technology that makes a real difference in neonatal care.
Spinal tap procedures in infants and neonates present unique challenges for healthcare providers. Our technology is designed to address these challenges head-on, improving procedural accuracy and patient outcomes while reducing stress for both medical professionals and families.
Part of Something Bigger
We’re joining an impressive cohort of companies advancing breakthrough work across neuroscience, oncology, women’s health, regenerative medicine, and next-generation medical technologies. Together, we represent the breadth and depth of innovation happening right here in Rhode Island.
As Governor Dan McKee noted, “These latest investments further strengthen Rhode Island’s position in one of the fastest-growing sectors of the economy. By supporting companies that are choosing to build and scale here, we’re attracting new jobs, strengthening our tax base, and positioning Rhode Island as a serious player in the life sciences market.”
Looking Ahead
With RILSH having now deployed more than $20 million since its inception, Rhode Island is demonstrating a serious commitment to building a world-class life sciences hub. For Smöltap, this means access to not just funding, but also a growing network of resources, talent, and expertise that will help us bring our vision to market faster.
We’re grateful to RILSH, Governor McKee, and the entire Rhode Island life sciences community for believing in our mission. This is just the beginning of our journey to improve neonatal care, and we couldn’t ask for a better place to do it than right here in Providence.
About Smoltap
Smöltap is a Providence-based medical technology company developing innovative solutions to improve infant and neonatal spinal tap procedures. Our Class I device aims to enhance procedural accuracy, reduce complications, and improve outcomes for our smallest patients.
About Rhode Island Life Science Hub
The Rhode Island Life Science Hub is a state-supported organization dedicated to growing Rhode Island’s life sciences ecosystem. Through strategic investments, infrastructure development, and community building, RILSH is positioning Rhode Island as a competitive destination for life sciences innovation and driving long-term economic growth for the state.